Payment overview · 2025
General Payments
$1,300.97
69 reported records · 19 companies
Healthcare provider profile · identity verified
Anas Entabi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PALMDALE, CA · NPI 1669465258
Verified facts
What the public records show
CMS Open Payments records show Anas Entabi, M.D. received $1,300.97 in general payments during 2025 across 69 reported records.
Novo Nordisk Inc accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $222.03 | 17.1% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $189.81 | 14.6% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.99 | 11.9% | 13 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $126.45 | 9.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.77 | 7.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.66 | 5.9% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.83 | 5.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.20 | 4.3% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $42.19 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.69 | 2.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.55 | 2.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $33.04 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.89 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.99 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.58 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.00 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.49 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.96 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,215.97 | 67 |
| Education | $85.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $192.96 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $138.04 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $138.04 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.09 | 6 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $126.45 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $102.77 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.66 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $68.83 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.20 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $42.19 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $33.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 169 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1176 | 407 |
| Amlodipine Besylate | Amlodipine Besylate | 1128 | 377 |
| Levothyroxine Sodium | Levothyroxine Sodium | 754 | 236 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 741 | 117 |
| Lisinopril | Lisinopril | 724 | 244 |
| Losartan Potassium | Losartan Potassium | 719 | 248 |
| Metformin Hcl | Metformin Hcl | 679 | 233 |
| Omeprazole | Omeprazole | 488 | 169 |
| Gabapentin | Gabapentin | 471 | 148 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 418 | 138 |
| Tamsulosin Hcl | Tamsulosin Hcl | 370 | 122 |
| Naproxen | Naproxen | 357 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 111 |
| Glipizide | Glipizide | 316 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 107 |
| Simvastatin | Simvastatin | 297 | 97 |
| Temazepam | Temazepam | 285 | 70 |
| Azithromycin | Azithromycin | 278 | 199 |
| Tramadol Hcl | Tramadol Hcl | 274 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 88 |
| Hydralazine Hcl | Hydralazine Hcl | 269 | 70 |
| Alendronate Sodium | Alendronate Sodium | 261 | 93 |
| Baclofen | Baclofen | 246 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 238 | 101 |
| Ibuprofen | Ibuprofen | 238 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 237 | 32 |
| Furosemide | Furosemide | 235 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 46 |
| Eliquis | Apixaban | 220 | 56 |
| Famotidine | Famotidine | 211 | 87 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 211 | 99 |
| Benazepril Hcl | Benazepril Hcl | 193 | 58 |
| Atenolol | Atenolol | 177 | 53 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 171 | 95 |
| Januvia | Sitagliptin Phosphate | 170 | 57 |
| Jardiance | Empagliflozin | 169 | 65 |
| Donepezil Hcl | Donepezil Hcl | 153 | 49 |
| Clonidine Hcl | Clonidine Hcl | 152 | 42 |
| Alprazolam | Alprazolam | 151 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 144 | 114 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 52 |
| Meclizine Hcl | Meclizine Hcl | 142 | 70 |
| Allopurinol | Allopurinol | 127 | 37 |
| Pregabalin | Pregabalin | 119 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 40 |
| Methylprednisolone | Methylprednisolone | 113 | 84 |
| Sertraline Hcl | Sertraline Hcl | 112 | 35 |
| Lactulose | Lactulose | 109 | 56 |
| Carvedilol | Carvedilol | 108 | 32 |
| Glimepiride | Glimepiride | 108 | 38 |
| Sildenafil Citrate | Sildenafil Citrate | 102 | 25 |
| Montelukast Sodium | Montelukast Sodium | 99 | 30 |
| Lorazepam | Lorazepam | 98 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 36 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 90 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 26 |
| Trazodone Hcl | Trazodone Hcl | 90 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 20 |
| Valsartan | Valsartan | 79 | 31 |
| Cephalexin | Cephalexin | 77 | 60 |
| Memantine Hcl | Memantine Hcl | 77 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 76 | 18 |
| Ozempic | Semaglutide | 70 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 57 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 12 |
| Xarelto | Rivaroxaban | 63 | 19 |
| Meloxicam | Meloxicam | 62 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 16 |
| Levetiracetam | Levetiracetam | 58 | 13 |
| Lovastatin | Lovastatin | 55 | 17 |
| Acyclovir | Acyclovir | 53 | 16 |
| Hydrocortisone | Hydrocortisone | 53 | 25 |
| Potassium Chloride | Potassium Chloride | 53 | 22 |
| Rybelsus | Semaglutide | 53 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 26 |
| Dutasteride | Dutasteride | 50 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 15 |
| Celecoxib | Celecoxib | 44 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 15 |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | 19 |
| Clotrimazole | Clotrimazole | 39 | 26 |
| Metronidazole | Metronidazole | 39 | 31 |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 13 |
| Spironolactone | Spironolactone | 37 | 16 |
| Constulose | Lactulose | 36 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 33 |
| Gemfibrozil | Gemfibrozil | 35 | 13 |
| Nystatin | Nystatin | 35 | 19 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 24 |
| Linzess | Linaclotide | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 14 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 25 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Prolia | Denosumab | 19 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,300.97 · 69 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, AUSTEDO XR, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, INGREZZA, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error